All posts by imreal

Emergency Medicine Expert Dr. Yaritza Arriaga-O’Neill Joins Exclusive Haute Beauty Network


Dr. Yaritza Arriaga-O’Neill

Patients appreciate the warm and welcoming approach Dr. Arriaga-O’Neill takes. She never rushes visits, and patient education is part of each interaction.

Yaritza Arriaga-O’Neill, MD, FAAEM, is a highly skilled physician with a passion for delivering top-quality, personalized care. Through her work at Highway Integrative Health Center in Davenport, Florida, Dr. Arriaga O’Neill enjoys helping patients meet their acute care needs, delivering preventive health services, and chronic disease management.

Education has always been a guiding force in Dr. Arriaga-O’Neill’s life. She completed her undergraduate degree at Universidad de Puerto Rico (UPR) in Rio Piedras before moving on to medical school at Universidad Autónoma de Guadalajara (UAG) in Jalisco, Mexico. She then completed a fifth pathway program and emergency medicine training in Puerto Rico. To this day, Dr. Arriaga-O’Neill continues to learn and evolve.

With over a decade of experience, Dr. Arriaga-O’Neill has provided accurate care to adults and pediatrics. Patients appreciate the warm and welcoming approach Dr. Arriaga-O’Neill takes. She never rushes visits, and patient education is part of each interaction. Her goal is to partner with the patient and find the root of their problems. This empowers patients to take an active role in shaping their health and wellness future.

About Highway Integrative Health Center:

Highway Integrative Health Center is unlike other urgent or primary care offices as they offer a wide range of services, including preventative care, IV Therapy, comprehensive physical exams, lab testing, personalized primary care, and to add to the already fabulous mix, Botox.

If you want to look as good as you feel, you are invited to partner with Dr. Arriaga-O’Neill for all of your healthcare and aesthetic needs.

Learn more about Dr. Yaritza Arriaga-O’Neill by visiting: https://hauteliving.com/hautebeauty/member/dr-yaritza-arriaga-oneill/

ABOUT HAUTE BEAUTY NETWORK:

Haute Beauty is affiliated with the luxury lifestyle publication Haute Living. As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.

For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/

Share article on social media or email:

Internal Medicine Expert Dr. Deborah Houk Joins Exclusive Haute MD Network


Dr. Deborah Houk

Along with her expertise in a vast array of common medical conditions, she also specializes in individualized coaching, mentorship, and helping others become their best selves.

Dr. Deborah Houk, MD, provides exceptional medical care in Naples, FL as an Internal Medicine Hospitalist Physician. She currently sees inpatients at Physicians Regional Medical Center and is expanding to provide care for those at Naples Community Hospital. Along with her expertise in a vast array of common medical conditions such as heart failure, diabetes, COPD, cancer, blood conditions, and more, she also specializes in individualized coaching, mentorship, and helping others become their best selves.

Dr. Houk is board certified in Internal Medicine. Dr. Houk received both her undergraduate and master’s degrees from Stanford University in Palo Alto, California, within 4 years. From there, she relocated to Washington, D.C., where she earned her medical degree at The George Washington University. Dr. Houk then completed her internship and residency training in internal medicine at Yale-New Haven Hospital in New Haven, Connecticut. Dr. Houk then became the Director of Hospital Medicine at the prestigious Ochsner Clinic Foundation in New Orleans before moving to Naples, Florida, and taking on her role as a hospitalist for the Naples community and an executive committee member of Naples Heart Rhythm Specialists.

Learn more about Dr. Deborah Houk by visiting: https://hauteliving.com/hautebeauty/mdmember/dr-deborah-houk/

ABOUT HAUTE MD NETWORK:

Haute Beauty is affiliated with the luxury lifestyle publication Haute Living. As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.

For more about Haute MD, visit https://hauteliving.com/hautebeauty/mdmember/

Share article on social media or email:

Windsor Care Centers in Northern California Host 2-Day Educational Summit


Windsor Northern California Region

“I wanted to provide a forum for the Administrators and DONs to come together for in-person education, collaboration, and team building,” says Kristine Perry, Windsor’s Northern California Regional Director of Operations.

Seven Windsor care centers, providers of rehabilitation and short- and long-term care, recently gathered in Northern California for two days of collaboration, learning, networking and team-building.

Organized and hosted by Windsor’s Northern California Regional Director of Operations, Kristine Perry, the theme of the two-day summit was “Red Carpet VIP Event.” It was attended by the Administrators and Directors of Nursing for the seven Northern California facilities, plus Northern CA regional team leaders, including the clinical directors, senior human resources representatives, directors of business development, facilities maintenance, and MDS.

Perry utilized the summit to welcome new management to the organization, review important corporate policies, train the staff on the latest clinical updates, review regulatory and compliance updates, network with strategic partners, and build a stronger sense of camaraderie and teamwork within her region.

“I wanted to provide a forum for the Administrators and DONs to come together for in-person education, collaboration, and team building,” says Perry. “The theme of the event was Red Carpet – VIP. As part of our region’s commitment to recruitment and retention, our Administrators and DONs have been rolling out the red carpet to welcome new team members on their first day of orientation. I wanted to roll out the red carpet for them to provide them with the same experience.”

Share article on social media or email:

FDA Commissioner Robert Califf’s Post-PDUFA, Post-COVID FDA Agenda Webinar on Sept. 15, 2022


FDA Commissioner Califf’s Post-PDUFA, Post-COVID FDA Agenda

Key Developments, Insights and Analysis

An FDAnews Webinar Special Extended Edition

Thursday, Sept. 15, 2022, 1:30 p.m.–4:30 p.m. EDT

https://wcg.swoogo.com/califfs-post-pdufa-post-covid-fda-agenda

With a new commissioner and his staff on board at the FDA, with PDUFA VII about to be implemented, and with a new normal developing as the pandemic wanes, there will be significant changes at the FDA.

As Dr. Robert Califf takes the FDA reins a second time, he’s facing a whole new world and setting new priorities for the agency.

The presenters will provide a close analysis of 2022 under the Biden and Califf regimes, keen insight on what to anticipate in the future, and practical guidance on how to adapt to the new FDA.

Wayne L. Pines, president of healthcare at APCO Worldwide and former associate commissioner of the FDA, along with a panel of experts, will share what pharmaceutical and medical device professionals must know and do to get ahead of the changes.

They will look back at the crucial developments of 2022 and will discuss what will likely come in 2023, including how the multiple lessons of the pandemic will be applied to daily FDA activities, what enforcement will look like, likely inspection process innovations and more, such as:


  • What new provisions in the user fee legislation will affect daily business
  • The importance of the recent drug importation guidance and the impact of new guidances
  • How key personnel changes at FDA will make a impact
  • The impact of drug-related “crises” on CDER’s approach to R&D and approvals
  • What to expect in terms of more use of emergency authorizations, accelerated approvals, breakthrough and fast-track programs, OTC drug monograph reviews, adaptive trials
  • Key elements of CBER’s five-point plan
  • Expanded opportunities in regenerative medicine
  • Regulation of AI and software as a medical device
  • Harmonization efforts with the EU
  • Inspection policies and procedures
  • Advertising and promotion policies and enforcement


Webinar Details

FDA Commissioner Califf’s Post-PDUFA, Post-COVID FDA Agenda

Key Developments, Insights and Analysis

An FDAnews Webinar Special Extended Edition

Thursday, Sept. 15, 2022, 1:30 p.m.–4:30 p.m. EDT

https://wcg.swoogo.com/califfs-post-pdufa-post-covid-fda-agenda

Price:

$337

Easy Ways to Order:

Online: https://wcg.swoogo.com/califfs-post-pdufa-post-covid-fda-agenda

By phone: 888.838.5578 or 703.538.7600

About WCG FDAnews:

WCG FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on WCG FDAnews’ newsletters, books, databases, webinars and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations. Learn more at fdanews.com.

Share article on social media or email:

RESTEM and JAR of Hope Foundation Announce Strategic Partnership and Clinical Trial Launch of Next-Generation Cell Therapy for Patients with Duchenne Muscular Dystrophy


“As a pioneering next-generation, clinical-stage cell therapy company we honored to have the support of JAR of Hope to provide the critically important financial support to bring this novel therapeutic approach to children with Duchenne Muscular Dystrophy”, said David Pyrce, CEO of RESTEM.

RESTEM, a pioneering, next-generation, clinical-stage cell therapy company focused on harnessing the unique power of cell therapy and JAR of Hope, a 501(3)(C) non-profit foundation dedicated to ongoing research efforts to find a cure for Duchenne Muscular Dystrophy (DMD), today announced a strategic collaboration and launch of a landmark clinical trial to evaluate RESTEM’s novel, umbilical cord lining stem cell (ULSC) therapy for the treatment of Duchenne Muscular Dystrophy.

The Phase I trial will include 12 patients who will receive intravenous infusions of ULSCs to treat DMD, which is a severe type of muscular dystrophy that primarily affects boys. Muscle weakness usually begins around the age of four, with rapid symptom progression. Most young boys are wheelchair-bound by the age of twelve.

The trial, which has received authorization to proceed from the U.S. Food and Drug Administration (FDA), seeks to provide early clinical evidence of the potential of this novel cell therapy to improve the health of DMD patients and is the first clinical trial focused on evaluating ULSCs in DMD. If the Phase I trial is successful, a Phase II trial is expected to follow, which will assess effectiveness of ULSC therapy in a larger number of DMD patients.

“As a pioneering next-generation, clinical-stage cell therapy company committed to advancing game-changing cell-based therapeutics, we are honored to have the support of JAR of Hope to provide the critically important financial support to bring this novel therapeutic approach to children with Duchenne Muscular Dystrophy”, said David Pyrce, CEO of RESTEM.

“DMD is an extremely serious disease that over time can affect all voluntary muscles, including the heart and breathing muscles in later stages of the disease resulting in significantly shortened life expectancy. With few effective therapies available, there is a significant need for better treatment options and this trial, using RESTEM’s novel, umbilical cord lining stem cell therapy, offers the potential to improve or slow disease progression with hopes of giving these children a more carefree childhood and an improved quality of life,” said James Raffone, Founder and CEO of JAR of Hope.

Mr. Raffone continued, “JAR of Hope was born because no child should have to suffer or die from DMD and no family should have to suffer from the devastating consequences of this disease. Our mission is to better educate, raise awareness and provide funding for innovative new treatment options that potentially will lead to a cure for DMD, giving children to get the chance to become healthy adults. Our goal is to one day see the words Duchenne muscular dystrophy only in history book, just like polio. We are pleased to have the opportunity to provide the financial support for this clinical trial with transformative potential using a novel cell therapy approach as the first step down the path to a cure for DMD. We encourage others to join with us in our relentless pursuit to find a cure for DMD.”

“We are thrilled to have the opportunity to bring this potentially transformative therapy, based on over a decade of research, to Duchenne Muscular Dystrophy patients”, said Rafael Gonzalez, Ph.D., Senior Vice President of Research and Development at RESTEM. “We are honored to have the generous financial support from JAR of Hope to bring this potentially game-changing therapy to DMD patients as quickly as possible.”

Dr.Gonzalez continued, “Our mission is to fast-track the development of transformative new therapies for serious, life-threatening diseases, with a laser-focus on fast-tracking the launch of this study evaluating the potential effectiveness of our novel and proprietary umbilical cord lining stem cell therapy in patients with DMD.”

Clinical Trial Overview RESTEM has received FDA authorization for its Investigational New Drug Application (IND) entitled “A Phase I, randomized, double-blind, placebo-controlled cross over study to assess the safety, tolerability, and preliminary efficacy of Umbilical Cord Lining stem cells (ULSC) in pediatric patients with Duchenne Muscular Dystrophy (DMD)”. The trial is planned to enroll 12 patients. In previous clinical trials in other indications, RESTEM’s ULSCs have demonstrated an excellent safety record with promising clinical results achieved across a range of indications. If encouraging clinical results are achieved in this Phase I study, a Phase II trial is planned, with the goal of bringing this potentially transformative new therapeutic option to patients with DMD as quickly as possible.

About Duchenne Muscular Dystrophy

DMD is a rapidly progressive form of muscular dystrophy that occurs primarily in boys. It is caused by an alteration (mutation) in a gene, called the DMD gene that can be inherited in families in an X-linked recessive fashion, but it often occurs in people from families without a known history of the condition. Individuals who have DMD have progressive loss of muscle function and weakness, which begins in the lower limbs. Children with Duchenne Muscular Dystrophy do not produce the muscle protein dystrophin, which is encoded by the DMD gene and is crucial for muscle structure and function. Duchenne muscular dystrophy affects approximately 1 in 3500 male births worldwide. Because this is an inherited disorder, risks include a family history of Duchenne Muscular Dystrophy.

About RESTEM

RESTEM is a pioneering, innovation-driven, clinical-stage, biotechnology firm based in Corona, California, dedicated to the discovery, development and commercialization of novel, next-generation, cell-based therapeutics and tools that aid in the treatment of a broad range of degenerative disorders. The company’s mission is focused on improving the quality of life for those who suffer from disabling diseases of the immune system, age-associated disorders, and other degenerative diseases. The company is based on over 14 years of research and development focused on the company’s novel and proprietary umbilical cord lining stem cell therapy, or ULSCs, which have demonstrated promising regenerative properties in preclinical and human clinical trials. With an established strong leadership position, we continue to seek to be a major contributor to next-generation, cell-based therapies with ongoing clinical trials that address significant unmet medical need across a range of diseases and disorders. For additional information, please visit, https://restem.com/.

About JAR of Hope

JAR of Hope was born on September 13th, 2013, when the founder, Jim Raffone’s precious son, James (“Jamesy”) Anthony Raffone, was diagnosed with Duchenne Muscular Dystrophy (DMD). JAR of Hope’s mission is to find a cure for DMD.

Jamesy was 4 years old when he was diagnosed. Today he is 13. Each day without a cure his muscles continue to waste away as will all children who suffer from this horrific disease. Statistically, by the age of 12 they will be in a wheelchair, by 15 they will be a quadriplegic, by 18 they will not be able to breathe on their own and eventually will live on a ventilator until their bodies are no longer strong enough to fight this disease. Many don’t survive past their mid-20s. The only way this disease will continue to cheat these children of a future is if we stand by and do nothing to find a cure.

DMD is a genetic disorder characterized by progressive muscle degeneration. It primarily affects boys, although there are a few rare cases of girls who have DMD. Duchenne affects 300,000 boys worldwide; 20,000 children in the United States alone. These children are robbed of their childhood as they can’t run and play.

In over 200 years, a cure for Duchenne has not yet been found. Not one child has survived this disease, and as you can probably imagine, it takes millions of dollars, massive amounts of time and people committed to finding a cure. JAR of Hope has and continues to dedicate each and every day to finding a cure and living in a world where Duchenne no longer exists. With the help of donors and sponsors, JAR of Hope is funding a team of research scientists and doctors determined to eliminate Duchenne. We also provide financial and emotional support for children and their families who are and have been affected by DMD. We have purchased wheelchair accessible vans, installed chair lifts on stairs in homes for these children to be able to move from one floor to another, funded studies, assisted with medical bills and, unfortunately, have paid for funeral expenses for children that have lost their fight to Duchenne MD.

JAR of Hope’s founder, Jim Raffone, has been relentless in his pursuit to defeat Duchenne. Some of his efforts in educating others, raising awareness and funds include breathtaking world-record events such as climbing Mt. Everest, creating race teams to participate in marathons and ultra marathons around the world, gathering thousands of people to simultaneously do pushups together, and creating the longest Lego chain at a school in New Jersey, to name a few. You can see the many events that have taken place on JAR of Hope’s website. Jim has received Keys to Cities from various Governors and Mayors as he has traversed around the globe determined to make Duchenne a household name and push science forward. Jamesy is the inspiration behind JAR of Hope and Jim is committed to all of the children with DMD around the world. Jamesy’s courage, strength, positive attitude and willingness to do whatever it takes to get healthier and stronger every day motivates Jim to carry on until the first child is cured. Jim and the JAR of Hope team believes that this disease has gone on for too long. Jim’s motto is: “I can, I will & I must” find a cure; however, he knows that he cannot do it alone. Together, we can make history and save lives. To learn more, please see https://www.jarofhope.org/.

For more information, please contact:

Rafael Gonzalez, PhD

Founder and SVP R&D

RESTEM, LLC

rgonzalez@restem.com

https://restem.com/

James Raffone

Founder & CEO

JAR of Hope

james@jarofhope.org

https://www.jarofhope.org/

Foria Announces Its Expansion Into Ulta Beauty Stores As Part Of Intimate Wellness Launch


This week, Foria, the 100% plant-based sexual wellness company, announces its expansion into The Wellness Shop at Ulta Beauty, as the leading retailer expands its assortment to debut Intimate Wellness.

Foria’s collection of intimacy and relief offerings are now available at select Ulta Beauty locations and online at http://www.ulta.com, including hero product, Awaken Arousal Oil with CBD, the recently-launched Breast Oil, best-selling Intimacy Sex Oil with CBD, CBD Salve, Intimacy Bath Salts, and soothing Relief & Intimacy Melts, among others.

“At Foria, we are thrilled to join The Wellness Shop at this exciting moment as Ulta Beauty elevates Intimate Wellness. For us, this partnership increases access to and education around intimacy, thus furthering our mission to make pleasure more accessible to all,” says Foria’s Co-Founder and CEO, Jon Brandon. “We know many people seek support when it comes to intimacy and they have not always been able to access products or information to meet their needs and desires. This milestone represents a meaningful step forward and we’re honored to be among the first products joining this pillar of The Wellness Shop at Ulta Beauty.”

“At Ulta Beauty, we are guest-centric in everything we do – and we know our guests’ beauty needs and wants are more interconnected to wellness than ever before,” says Penny Coy, Vice President of Merchandising at Ulta Beauty. “We are thrilled to expand The Wellness Shop to reflect more self-care needs with our Intimate Wellness offerings and could not be happier to welcome Foria to the Ulta Beauty family. The innovative brand is committed to its consumers, continual education and efficacy and it is a welcome addition to our assortment.”

Founded in 2014, Foria is the first brand to launch CBD-based sexual wellness products and continues to be a pioneer in the category, with products formulated to address common experiences and unmet needs across one’s lifetime. With a product line built on organic botanicals and broad spectrum CBD from USDA organic and regeneratively grown hemp, Foria effectively created the category for 100% plant-based sexual wellness.

In an effort to provide greater access to pleasure and in recognition that not every plant is for every body, the brand also recently launched two new botanically-formulated, CBD-free products. Committed to maintaining the highest standards of transparency, for people, plants, and the planet, Foria takes “clean” to a whole new level – all of their Intimacy formulas use 100% all-natural and organic botanicals and have no fragrances, additives, or synthetics, ever.

Foria’s products are also available for nationwide shipping via http://www.foriawellness.com as well as at Nordstrom, Neiman Marcus, Madewell, Thrive Market, Saks Fifth Avenue, The Skinstore, Look Fantastic and many more. The full Foria retail store locator is available here, which now includes their Ulta Beauty locations.

For media inquiries, please contact RVD Communications at press@foriawellness.com.

About Foria

Foria is an innovative health and sexual wellness company creating life-changing, plant-based sexual wellness formulas for relief, intimacy, and daily wellbeing. Rooted in the belief that pleasure is your nature, Foria is on a mission to make more pleasure accessible to more people, while maintaining the highest standards of transparency – for people, plants, and the planet.

Through an unwavering commitment to clean ingredients, sex education, and sustainable packaging, Foria crafts formulas rooted in the sensuality of nature and designed to connect you to your body. Offerings include Awaken, Foria’s hero arousal oil, a luxurious Sex Oil lubricant, relaxing Bath Salts, tension-easing Salve and Melts, and much more.

Foria products go through rigorous development and ingredient testing to meet a standard not often seen in the industry – and it is one of the only brands that provides transparent third-party testing reports for all of its ingredients. During this process, if any ingredient doesn’t meet Foria’s standards, it is reformulated or sourced from a different supplier. The brand also provides a Certificate of Analysis (COA) for every product they sell, furthering its commitment to the health and wellness of its community.

Most recently, as part of Foria’s mission to close the pleasure gap and make pleasure and wellness accessible to all, the brand has expanded its line to include botanical CBD-Free products: including an arousal oil with botanicals and a sensual breast oil.

###

Share article on social media or email:

New ASNC-led Guideline Details How to Use CT in Hybrid Nuclear-CT Cardiac Imaging


ASNC

Hybrid Imaging Guideline

“Hybrid imaging is helping cardiology teams enhance image quality and obtain new information that impact treatment decisions and our patients’ long-term outcomes,” says ASNC President-elect Mouaz H. Al-Mallah, MD, MSc, FASNC.

The American Society of Nuclear Cardiology (ASNC) and three partner societies have come together to answer cardiac imagers’ questions about SPECT/CT and PET/CT imaging with attenuation correction, localization of radiotracer uptake and coronary artery calcium scoring (CACS). In a new multisociety guideline published today in the Journal of Nuclear Cardiology, the organizations recommend training and competency requirements for imaging physicians and technologists; describe models for collaborative, cross-specialty study interpretation and reporting; and suggest solutions for the preauthorization and reimbursement challenges that some labs have faced with hybrid imaging in nuclear cardiology.

Authored and endorsed by ASNC and the American Association of Physicists in Medicine (AAPM), Society of Cardiovascular Computed Tomography (SCCT) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the new guideline highlights how SPECT/CT and PET/CT testing improve diagnostic accuracy and risk-stratification in patients with known or suspected coronary artery disease as well as the clinical value of hybrid nuclear-CT imaging in assessing infection, inflammation, viability and hibernation in cardiac patients.

“Hybrid imaging is helping cardiology teams enhance image quality and obtain new information that impact treatment decisions and our patients’ long-term outcomes,” says ASNC President-elect Mouaz H. Al-Mallah, MD, MSc, FASNC, cardiac PET chair at Houston Methodist DeBakey Heart and Vascular Center and the new guideline’s lead author. “Assessing atherosclerosis burden in hybrid imaging improves the diagnostic accuracy of MPI studies and help clinicians identify high-risk patients and treat them accordingly. The question is not whether today’s cardiac imaging labs should adopt hybrid imaging but rather how to adapt their labs for the routine use of SPECT/CT and PET/CT. There are practical day-to-day issues that can become obstacles for labs. We developed this guideline to show the options available for managing the practical issues, thus making hybrid nuclear-CT imaging more accessible for patients who will benefit from it.”

Imaging teams will find the new guideline is a blueprint for modernizing their labs for the delivery of hybrid nuclear-CT imaging.

Step by step, the guideline provides detailed discussion, tables and figures explaining –

  • Hardware, software and image acquisition requirements
  • Quality control issues, including a list of artifacts that imaging professionals must understand to ensure proper study interpretation and avoid unnecessarily repeated tests
  • Four study interpretation models that imagers may choose from to ensure the high-quality reading and reporting of extracardiac findings from CT scans performed during hybrid imaging
  • How to approach standardized integrated hybrid nuclear-CT reports, including the key cardiovascular diagnosis and non-cardiovascular incidental findings that should be reported
  • Current training and licensing requirements and certification standards for technologists and physicians
  • Recommendations for competency standards, including necessary skillsets, continuing education credits and case volumes
  •      Coding and billing requirements
  •      How to resolve common preauthorization challenges

ASNC is committed to providing imagers with the knowledge and tools needed to make their transition to hybrid imaging smooth and successful. The ASNC2022 conference will feature ASNC’s inaugural Hybrid Imaging Symposium, which will examine the key concepts in the new guideline and use real-world cases to demonstrate how imaging professionals can break down technical, training and financial barriers that may be keeping some labs from adopting hybrid nuclear-CT imaging.

ASNC’s Hybrid Imaging Symposium will be delivered in two parts:

  • Part 1 is currently available OnDemand on the ASNC2022 online meeting platform.
  • Part 2 will be delivered live Thursday, Sept. 8, at ASNC2022 in Orlando, Florida. This interactive event will feature a panel of experienced hybrid imagers who have used different hardware, software and models in their labs.

The 2022 ASNC/AAPM/SCCT/SNMMI Guideline for the Use of CT in Hybrid Nuclear/CT Cardiac Imaging may be downloaded from the Journal of Nuclear Cardiology.

To register to attend the ASNC2022 Hybrid Imaging Symposium and other educational sessions or to arrange interviews with ASNC experts, members of the media should contact Jennifer Taylor Howell at jhowell@asnc.org.

###

About the American Society of Nuclear Cardiology

For over 25 years, the American Society of Nuclear Cardiology and its more than 4,500 members have been improving cardiovascular outcomes through image-guided patient management. As the only society dedicated solely to the field of nuclear cardiology, ASNC establishes standards for excellence in cardiovascular imaging through the development of clinical guidelines, professional medical education, advocacy and research development. ASNC provides peer-reviewed original articles through its official publication Journal of Nuclear Cardiology and operates the nation’s first noninvasive cardiac imaging registry, ImageGuide Registry®, to benchmark quality and improve patient care. For more information, visit http://www.asnc.org.

Share article on social media or email:

Political Squabbles Slow Drug Development for Rare Diseases


News Image

The current process for developing new treatments for rare diseases leaves India and the Indian diaspora on the outside looking in.

The U.S. Food and Drug Administration, the key regulatory agency governing clinical trials in the US, has been slow to address the known lack of diversity in drug research & development. It has also been an agency beset by external political forces as different factions angled for control of the COVID-19 pandemic response. The agency lacked a full-time chief commissioner for over a year, slowing reform efforts. Recent controversies over approved drugs that lack verifiable efficacy have further muddled attempts to diversify evidence-gathering systems.

FDA-approved clinical trials have historically lacked diversity among the participants. Research shows that as recently as 2021, including during the COVID vaccine clinical trials, about 80% of clinical trial participants were white adults, mostly males, from affluent socioeconomic backgrounds. Trials are often based in majority-white regions of the world. This denies people of color, non-English speaking, underrepresented minorities, and people in low-and-middle-income countries (LMICs), such as India, access to critical life-saving therapies and clinical trials related to rare and common diseases.(1)

The Indian subcontinent is home to about a quarter of the world’s population. The Indian diaspora (the dispersion of any people from their original homeland) is the largest in the world, comprising more than 4.2 million people in the US alone. Yet less than 2% of global clinical trials have any study sites in India. Moreover, clinical trial participants do not reflect the racial and ethnic makeup of the global population affected by the targeted disease. Drug development is meant to provide treatments for the general population, but participants in drug trials lack representative diversity.

This lack of diversity in patient clinical trials is counter-productive to research goals, particularly in studies involving ultra-rare diseases where a small number of affected patients are sparsely distributed geographically within the US and globally. Without a diverse base of study participants, researchers lack accurate data on comparisons of disease progression and treatment efficacy. The US Biopharma industry struggles to enroll the required number of patients in orphan drugs (a pharmaceutical drug that, for the most part, has not been developed commercially due to limited potential for profitability) clinical trials within the US, requiring a more global enrollment strategy. From the perspective of rare diseases patients located in LMICs, without local access to clinical trials, remain unable to access novel treatment options. Neither science nor patients are well-served, causing an increased burden on the orphan drug development process.

“The current process for developing new treatments for rare diseases leaves India and the Indian diaspora on the outside looking in,” says Harsha Rajasimha, Ph.D., Founder & Executive Chairman of the Indo-US Organization for Rare Diseases (IndoUSrare). “Indian patients miss out on opportunities to avail clinical research as a care option (CRAACO) or join a clinical trial that offers the best hope for timely care management. Then when drugs are eventually approved, they are based on safety and efficacy data from mostly non-Indian patients. It can be a long wait involving additional costs for a treatment that comes with a question mark about its safety and efficacy in the target Indian patient population.”

IndoUSrare leaders advocate for the inclusion of people of Indian origin in global clinical trials. This is especially true in certain rare genetic diseases, such as multiple sclerosis, muscular dystrophies, GNE myopathy, and blood-related disorders, such as hemophilia, thalassemia, and sickle cell disease, that disproportionately affect the Indian population.

Recent efforts by the Ministry of Health and Family Welfare (MoHFW) in India and the Indian regulatory agencies have ensured that research facilities meet international standards. Even before the COVID-19 pandemic, international pharmaceutical companies had already established research sites in India. The infrastructure is in place for India to be a productive site for global orphan drug clinical trials.(2)

In 2021, the Indian government revived the National Policy for Rare Diseases (NPRD) to assist people with rare diseases. In August 2022, the MoHFW issued a memorandum announcing financial support of up to INR (Indian Rupee) 5 million per patient with a rare disease falling into any of the three groups referenced in the NPRD towards the cost of treatment(s) and disease management. The eight centers of excellence (CoEs) for rare diseases recognized by the NPRD are already working with patients and medical geneticists to identify individuals needing this help. Researchers could build on these frameworks and develop trials that reflect the unmet needs of people in the subcontinent.(3)

“Given the massive number of persons of Indian origin living worldwide and the consanguinity [common ancestry] among various Indian ethnic groups resulting in a disproportionate prevalence of certain genetic diseases, there is an urgent need to develop strategies for inclusion of the diaspora in global research, development, and orphan drug launch planning,” says Dr. Rajasimha. “The access to a wider participant pool promises to speed up trial enrollment, particularly in one-and-done cell/gene therapy trials where sponsors are competing to enroll small patient populations in the US/EU. This will likely accelerate the time to market for the Sponsors and be likely supported through patient grants provided by the Indian Government of up to INR 5 million per patient. Certain public sector units in India also cover 100% of the healthcare costs for over 120 million people including their costs of treatments with no pre-set limits.

“I encourage the new leadership at the FDA to do more to quickly address this unmet need for diversity in clinical trials. We have submitted these perspectives and other ideas in response to FDA’s recent requests for public comments on their guidelines for DEI (6) and towards the development of global clinical trial networks.”

References;

1) https://health.economictimes.indiatimes.com/news/industry/addressing-massive-health-inequities-on-rare-disease-day/89736862

2) https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0000890

3) Nature. “When will clinical trials finally reflect diversity?” May 2018.

4) Perspectives in Clinical Research. “Why are clinical trials necessary in India?” April 2014.

5) Ministry of Health and Family Welfare. “Union Health Minister approves National Policy for Rare Diseases.” April 2021.

6) Comments to Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability. https://www.regulations.gov/docket/FDA-2021-D-0789

About IndoUSrare

IndoUSrare is a humanitarian non-profit 501(c)(3) tax-exempt public charity organization based in the U.S. Founder and Chairman, Dr. Harsha Rajasimha, who lost a child to a rare disease in 2012, has been a rare disease advocate for more than ten years. To address the unmet needs of diverse patients with rare diseases globally, the leadership team comprised of experienced professionals from research, advocacy, regulatory, and drug development seeks to build cross-border collaborations connecting stakeholders of rare diseases in low- and middle-income regions such as India, with their counterparts and clinical researchers in the U.S. to improve the diversity of clinical trial participants, accelerate research and development, and improve equitable access to life-saving therapies to diverse populations of rare disease patients. Visit https://indousrare.org

Share article on social media or email:

Boulder iQ Names Quality Assurance, Control Expert Melinda Sogo Director of Quality


Boulder iQ is an expert contract firm that provides life sciences companies all the services they need to bring products to market. With specialties in regulatory affairs, quality assurance, design, engineering, manufacturing and sterilization, the company’s single-source program speeds product development.

Boulder iQ

Melinda’s background as a scientist, in microbiology, cell biology and molecular biology assay development, complement her data management expertise in leading Boulder iQ’s advanced quality team.

Boulder iQ has named Melinda Sogo director of quality.

Sogo brings two decades of industry experience to the expert contract consulting firm, with particular expertise in document control, quality assurance and operations. Boulder iQ provides design engineering, development and turnkey manufacturing for consumer, high-technology and medical products, and regulatory, clinical and quality management system services for the medical device and in-vitro diagnostic industries.

Most recently, Sogo served as vice president of quality for VPI Compounding (Centennial, Colorado), and as senior vice president of quality and compliance for OraLabs, Inc. (Parker, Colorado). She has held the positions of quality control manager with WishGarden Herbs, Inc. (Louisville, Colorado) and director of quality management with STAQ Pharma, Inc. (Denver).

The new director also has worked in quality assurance management with ArcherDX, Inc. (Boulder, Colorado), and Sharklet Technologies, Inc. (Aurora, Colorado), and in quality documentation management with Venaxis (formerly AspenBio Pharma Labs, Inc.) in Castle Rock, Colorado. Early in her career, she worked as a research scientist with Venaxis.

Sogo holds a Master of Business Administration degree from American Intercontinental University (Schaumburg, Illinois) and a Bachelor of Arts degree from the University of Northern Colorado.

“Melinda’s experience in the development and administration of quality systems will be a critical asset to our clients,” says Jim Kasic, chairman and founder of Boulder iQ and its Boulder Sterilization Services division. “Her background as a scientist, in microbiology, cell biology and molecular biology assay development, complement her data management expertise in leading an advanced quality team here at Boulder iQ.”

Boulder iQ (http://www.boulderiq.com)

Boulder iQ is an expert contract firm that provides life sciences companies all the services they need to bring products to market. With specialties in regulatory affairs, quality assurance, design, engineering and manufacturing, the company’s single-source program speeds product development. The Boulder Sterilization Services division, providing quick-turn ethylene oxide sterilization, final assembly and packaging services, is the recent recipient of a $250,000 grant from the Colorado Office of Economic Development and International Trade’s Advanced Industries Accelerator Grant Program.

Based in Boulder, Colorado, Boulder iQ is ISO 13485:2016 certified through Boulder BioMed. The company’s Boulder Medical Device Accelerator provides equity investment in start-up companies seeking product development services, expert mentoring and infrastructure support.

Share article on social media or email:

Cancer Hope Network names three to Board of Trustees terms


New CHN trustees: Merry Jennifer Markham, Renu Vaish, Gregory D. Blake

L-R: Merry Jennifer Markham, MD; Renu Vaish; Gregory D. Blake, MS Ed

Cancer is isolating and scary. For 40+ years, CHN has been providing 1:1 support for people facing cancer. We are grateful that Dr. Markham, Ms. Vaish and Mr. Blake have joined the incredible group of trustees who bring business, industry and healthcare knowledge to bear for the clients we serve.

Cancer Hope Network recently elected three new members to the Board of Trustees.

“Cancer is isolating and scary. For more than 40 years, CHN has been providing 1:1 peer support for people facing cancer. That work has been led by an incredible group of trustees who bring business, industry and healthcare knowledge to bear for the clients we serve,” said Executive Director Cynthia Gutierrez Bernstein. “We’re honored that Dr. Markham, Ms. Vaish and Mr. Blake have joined this dedicated group of volunteers.”

Gregory D. Blake, M.S. Ed

Licensed Resident in Counseling – Resilience Counseling & Social Skills Center, LLC

“Cancer Hope Network is the oldest and one of the largest peer to peer cancer support networks in the country. It has been my privilege to serve this unique organization for the past two years as an Intern for my Masters of Mental Health program at the University of Pennsylvania. This experience not only exposed me to nearly every operational facet of CHN, but it also familiarized me with the high caliber and nimble expertise of its management and staff, and taught me just how massive the meaningful impact this group and its powerful volunteer corp is upon the lives of the people CHN serves. I view my position on the Board of Trustees as a continuation of my recent service role and I will endeavor to assist Cancer Hope Network to grow and thrive as it strives to meet the ever increasing needs of those stricken by cancer.”

Merry Jennifer Markham, M.D.

Chief of the Division of Hematology and Oncology – University of Florida College of Medicine Associate Director for Medical Affairs – UF Health Cancer Center

“As a medical oncologist caring for patients with gynecologic cancers, I see firsthand the need for and benefits of social support. Serving as a member of the Cancer Hope Network board is an opportunity to help provide that support. I’ve dedicated my life to serving people with cancer and it is an honor to contribute my time and professional expertise to help this organization flourish.”

Renu Vaish

Senior Vice President, Head of Regulatory – SpringWorks Therapeutics

My passion for hearing and focus on amplifying the patient voice is at the core of what inspires me. It motivates what I do on a daily basis. I’ve been a part of the pharmaceutical industry all my working life, with a unique opportunity to work alongside talented colleagues to advance patient care. Several of the therapies we’ve helped bring to patients have had profound impacts on the fight against cancer.

The Cancer Hope Network board is another team creating profoundly meaningful support for people facing cancer. I am thrilled to be part of this group and look forward to leveraging my expertise and network as part of this critical work.

To schedule an interview with Ms. Vaish, Mr. Blake or Dr. Markham, or to learn more about Cancer Hope Network, contact Sarah Miretti Cassidy, Director of External Affairs – 908.879.4039 or scassidy@cancerhopenetwork.org

ABOUT CHN

Cancer Hope Network provides free and confidential 1-1 peer support for cancer patients and their loved ones. CHN’s 400+ survivor and caregiver volunteers provide support from (pre)diagnosis, through treatment and into survivorship – including bereavement, when necessary.

Support Volunteers have faced more than 80 types of cancer. (More than 98% of the cancers that will be diagnosed this year.) They speak 15 languages, are located across the country, and are prepared to offer hope and guidance through a wide variety of challenges that accompany a cancer diagnosis.

All volunteer and client matches are overseen and supported from beginning to end by a team of healthcare and social work professionals.

Share article on social media or email: